LAUSR

tions have been reported following Oxford–AstraZeneca vaccination. Based on these findings, we hypothesize that delayed-type hypersensitivity reaction associated with polysorbate 80 can contribute to the occurrence of Wells’ syndrome. Further studies involving patch test for polysorbate 80 are necessary to confirm Oxford–AstraZeneca vaccine-induced delayed hypersensitivity reaction as the underlying mechanism. In conclusion, the development of Wells’ syndrome and Oxford–AstraZeneca COVID-19 vaccination may be related, with delayed-type hypersensitivity reaction as a possible mechanism. We believe that this rare case will broaden the understanding of Wells’ syndrome and raise awareness of the cutaneous side-effects of the Oxford–AstraZeneca COVID-19 vaccine.